SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AtheroGenics, Inc.{AGIX}-nasdaq
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Clarksterh9/11/2007 12:22:44 AM
   of 332
 
Another link courtesy of Trumangov. A summary of all the oral diabetes meds and their known efficacies and drawbacks:

annals.org

In summary - not much is known about the long term efficacy of most diabetes drugs on hard endpoints (I've seen only two randomized trials on hard endpoint - Actos on CAD and another trial on an agglomeration type endpoint of diabetes effects)

Metformin is the drug to beat from a benefit vs risk trade - and 1067 probably doesn't match it (CHF rate, liver tox). But it is probably in the same class as Actos etc. All based on slim evidence, so just me guesstimate.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News